As a world-leading service provider of antibody development and generation, Creative Biolabs is ready to provide a whole series of biomarker-specific in vitro diagnostic (IVD) antibody development services. A team of experienced scientists focused on antibody development are pleased to assist you in your project in a timely and cost-effective manner. Here, we introduce our IVD antibody development services targeting the mHLA-DR marker.
Monocyte Human Leukocyte Antigen-DR (mHLA-DR)
The human MHC (major histocompatibility complex) molecule, also called HLA (human leukocyte antigens) in human, is the cell surface antigen that mediates graft-versus-host disease. HLA-DR (Human Leukocyte Antigen-antigen D Related) is encoded by the human leukocyte antigen complex on chromosome 6 region 6p21.31, which works as an MHC class II cell surface receptor. It is an αβ heterodimer, each subunit contains two extracellular domains, a membrane-spanning domain, and a cytoplasmic tail. HLA-DR is expressed on B lymphocytes, monocytes, macrophages, activated T lymphocytes, activated NK lymphocytes, and human progenitor cells. And mHLA-DR is expressed on circulating monocytes. The complex of HLA-DR and its ligand constitutes a ligand for the T-cell receptor (TCR). The primary function of HLA-DR is to present peptide antigens to the immune system, for eliciting or suppressing T-(helper)-cell responses and eventually leading to the production of antibodies against the same peptide antigen.
Fig.1 3D ribbon models for HLA DR, HLA A, HLA DP and HLA B.( Patsopoulos, N. A., 2013)
The Role of mHLA-DR in Sepsis
As an MHC class II cell surface receptor, HLA-DR is involved in several autoimmune conditions, disease susceptibility and disease resistance. In the instance of an infection, HLA-DR molecules are upregulated in response to the peptides, such as the staphylococcal enterotoxin I peptide. In the meanwhile, the peptides are bound into a DR molecule and presented to a great many T-cell receptors found on T-helper cells. Then these cells bind to antigens on the surface of B-cells and stimulate B-cell proliferation. It is reported that there is a link between low levels of mHLA-DR and impairment of monocytic cellular functions, including loss of their pro-inflammatory properties and reduction of their capacity to induce antigen-specific T-cell responses. Monocyte-macrophages are important actors in the innate immune response. They link innate immunity to adaptive immunity and also are keys for the modulation of inflammation. So HLA-DR expression in circulating monocytes (mHLA-DR) as a marker of MHC class II has been proposed to characterize the innate immunity function in patients. Low mHLA-DR expression appears as a marker for monocytic dysfunctions and immunosuppression, temporarily presented in the majority of critically ill patients with sepsis. And the decrease in mHLA-DR expression is also a predictor of septic complications in sepsis, trauma injuries, postoperative, burns, pancreatitis, and stroke conditions. The monitoring of mHLA-DR could help to detect the patients at risk of sepsis.
IVD Antibody Development Services Targeting mHLA-DR Marker
In recent years, IVD technology is undergoing rapid development. IVD antibodies have been widely used in immunodiagnostic tools to aid in the diagnosis of various diseases, conditions, and infections. With years of experience and advanced technology, Creative Biolabs is able to provide a full range of high-quality and cost-effective biomarker-specific antibody development services. Especially, we help develop novel anti-mHLA-DR antibodies for your IVD projects. Having completed a number of IVD antibody generation and development projects, Creative Biolabs is confident to offer you the best products and services to promote your project a success.
If you are interested in the services we can provide, please don't hesitate to contact us or directly send us an inquiry. We will get in touch with you as soon as possible.
Reference
For Research Use Only.
